ADC Therapeutics Balances Solid Quarter With Trial Risk

ADC Therapeutics Ltd ((ADCT)) has held its Q1 earnings call. Read on for the main highlights of the call.

ADC Therapeutics’ latest earnings call struck a cautiously optimistic tone, blending tangible financial progress with clear clinical and execution risks. Management emphasized mid-teens revenue growth, disciplined cost control, and a cash runway into 2028, while underscoring that pivotal trial outcomes and lifecycle expansion will determine whether today’s solid base can translate into meaningful long-term value.

Steady Product Revenue Growth With Stable Underlying Demand

ADC Therapeutics reported Q1 2026 net product revenue of $20.0 million, up about 15% from $17.4 million a year earlier. Management attributed the increase largely to customer ordering variability, stressing that underlying demand for ZYNLONTA remains broadly stable rather than accelerating at this stage.

Cost Discipline Drives Lower Adjusted Operating Expenses

Total adjusted non-GAAP operating expenses fell to $42.9 million, a 13% year-on-year decline that reflects lower R&D spending and active cost management. The company framed this reduction as part of a deliberate effort to reallocate resources toward late-stage clinical and commercial priorities while maintaining core development capabilities.

Narrowing Losses Highlight Improving Profitability Trend

GAAP net loss improved to $33.0 million, or $0.21 per share, versus $38.6 million, or $0.36 per share, in Q1 2025, representing roughly a 14.5% improvement. On a non-GAAP basis, adjusted net loss narrowed to $19.7 million from $24.0 million, an almost 18% reduction that underscores the impact of expense controls.

Cash Runway Into 2028 Offsets Quarterly Burn Concerns

The company ended March 31 with $231.0 million in cash and equivalents, down from $261.3 million at year-end 2025, an 11.6% decline over the quarter. Even with this burn, management reiterated that its current balance supports operations at least into 2028, giving ADC Therapeutics time to see pivotal clinical readouts play out.

Pipeline Catalysts Centered On LOTIS-5, LOTIS-7 And IITs

Management flagged several near-term clinical and regulatory events, led by LOTIS-5, the Phase III confirmatory trial of ZYNLONTA plus rituximab, with top-line data expected before the end of June 2026 and an sBLA filing targeted by year-end if results are positive. LOTIS-7 enrollment is slated to complete in Q2 2026 with full data by year-end, while indolent lymphoma investigator-initiated trial data are anticipated between late 2026 and mid-2027.

Commercial Positioning Underpins Long-Term Revenue Ambitions

The company reiterated ZYNLONTA’s established role as a single-agent third-line-plus therapy in diffuse large B-cell lymphoma, positioning it as a foundation for future growth. Assuming successful lifecycle expansion and compendia and regulatory actions, management continues to project potential peak U.S. annual revenues in the $600 million to $1 billion range.

Softer Licensing And Royalty Streams Weigh On Comparisons

Non-product revenue was weaker in the quarter as licensing and royalty income fell compared with the prior year. The decline primarily reflected the absence of a $5 million milestone payment that boosted Q1 2025, creating tougher year-on-year comparisons for total revenue beyond ZYNLONTA sales.

Higher COGS Reflect Shifting Cost Base To Commercial Manufacturing

Cost of product sales rose to $3.6 million from about $2.0 million a year ago, an 80% increase driven by the reallocation of personnel costs from R&D into commercial manufacturing. Management signaled that this accounting shift will continue, keeping reported COGS elevated in coming quarters even as overall expenses remain under tighter control.

Cash Outflow Highlights Ongoing Need For Clinical Success

Quarter-over-quarter, cash and equivalents declined by $30.3 million, underscoring the company’s continued reliance on external funding or future revenue growth to reach breakeven. While management points to a 2028 runway, investors will be watching how this quarterly cash burn evolves as pivotal programs advance.

Binary Clinical Risk Around Blinded LOTIS-5 Data

Executives stressed that they remain fully blinded to LOTIS-5 data until database lock, limiting their ability to guide expectations around outcomes. They acknowledged that the readout represents a binary near-term risk, with a positive result enabling regulatory and compendia moves and a negative or ambiguous outcome materially constraining the company’s growth trajectory.

Limited 2026 Upside Despite Approaching Readout

Management cautioned that LOTIS-5 results, whatever the timing, are not expected to materially lift revenue in 2026 due to regulatory and commercial lead times. Any significant acceleration in sales is now framed as a 2027 and beyond event, contingent on a favorable outcome, approvals, and promotional ramp-up.

Quiet Period Tempers Near-Term Investor Communication

The company noted that it has been in a blackout or quiet period since April 1, limiting engagement with analysts and investors until LOTIS-5 top-line data are released. While this reduces near-term visibility, management suggested it is necessary to preserve the integrity of the pivotal trial and information flow.

Guidance Focuses On Data Timelines And Peak Potential

Looking ahead, ADC Therapeutics reaffirmed that LOTIS-5 top-line data are expected in Q2 2026, with a potential sBLA submission by year-end if results are positive and full publication and compendia inclusion targeted for the first half of 2027. The company also guided to completion of LOTIS-7 enrollment in Q2 with full data by year-end 2026 and reiterated its long-term U.S. peak revenue aspiration of $600 million to $1 billion for ZYNLONTA, supported by a cash runway extending into 2028.

ADC Therapeutics’ earnings call painted a picture of a company executing well on costs and sustaining modest revenue growth while waiting on pivotal clinical events that will define its next chapter. For investors, the story now hinges less on quarterly numbers and more on whether LOTIS-5 and related programs can unlock the sizable commercial potential management continues to outline.